The Next Top 5 FDA-Cleared Apps for Primary Care

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.